Diabetes drug may unlock kidney mineral mysteries in cystic disease
Knowledge-focused
Recruiting now
This study looks at how Empagliflozin, a diabetes drug, changes the way the kidneys handle calcium, phosphate, and magnesium in people with autosomal dominant polycystic kidney disease (ADPKD). About 40 adults will take either the drug or a placebo for 2 weeks, then switch after …
Phase: PHASE2 • Sponsor: Cantonal Hospital Graubuenden • Aim: Knowledge-focused
Last updated May 19, 2026 12:01 UTC